In agreement with our mouse data, FLT3L plasma levels were not altered in newly diagnosed IBD patients nor in chronic Crohn’s disease (CD) and ulcerative colitis (UC) patients compared to healthy donors (Fig. 4e). This evidence concerns the gene FLT3LG and inflammatory bowel disease.